Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial.

In 30 seconds

The Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial is a randomized controlled trial assessing the impact of automated red blood cell exchange (RBCX) on health outcomes in 173 adults with sickle cell disease (SCD) at high risk of death. The primary endpoint is the number of acute health care encounters or death over 13 months. Results are pending.

Key findings

• 173 participants were randomized across 23 sites in 3 countries.
• Participants had a mean age of 45.8 years and 54% were female.
• The average tricuspid regurgitant jet velocity was 2.8 m/s.
• The median eGFR in the cohort was 60 mL/min/1.73 m².

Why it matters

This trial addresses a critical gap in understanding the efficacy of RBCX in SCD patients at high risk of death, potentially guiding future treatment strategies and improving patient outcomes.